



## Clinical trial results:

### A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia

#### Summary

|                          |                 |
|--------------------------|-----------------|
| EudraCT number           | 2016-000061-23  |
| Trial protocol           | SK PL           |
| Global end of trial date | 31 January 2019 |

#### Results information

|                                |                 |
|--------------------------------|-----------------|
| Result version number          | v1 (current)    |
| This version publication date  | 26 January 2020 |
| First version publication date | 26 January 2020 |

#### Trial information

##### Trial identification

|                       |          |
|-----------------------|----------|
| Sponsor protocol code | D1001067 |
|-----------------------|----------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Sunovion Pharmaceuticals Inc.  |
| Sponsor organisation address | 84 Waterford Drive , Marlborough, United States, 01752   |
| Public contact               | CNS Medical Director, Sunovion Pharmaceuticals Inc., +1 866-503-6351, clinicaltrialdisclosure@sunovion.com |
| Scientific contact           | CNS Medical Director, Sunovion Pharmaceuticals Inc., +1 866-503-6351, clinicaltrialdisclosure@sunovion.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                 |
|--|-----------------|
| Analysis stage                                       | Final           |
| Date of interim/final analysis                       | 31 January 2019 |
| Is this the analysis of the primary completion data? | Yes             |
| Primary completion date                              | 31 January 2019 |
| Global end of trial reached?                         | Yes             |
| Global end of trial date                             | 31 January 2019 |
| Was the trial ended prematurely?                     | No              |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective is to evaluate the long-term safety of lurasidone (40 and 80 mg/day) in subjects with schizophrenia who have completed participation in Study D1001066.

Protection of trial subjects:

This study was conducted according to the protocol, International Council for Harmonization (ICH) Good Clinical Practice (GCP) and the ethical principles that have their origin in the Declaration of Helsinki

Background therapy: -

Evidence for comparator: -

|   |                 |
|---|-----------------|
| Actual start date of recruitment                          | 18 October 2016 |
| Long term follow-up planned                               | No              |
| Independent data monitoring committee (IDMC) involvement? | No              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Poland: 3              |
| Country: Number of subjects enrolled | Romania: 9             |
| Country: Number of subjects enrolled | Ukraine: 124           |
| Country: Number of subjects enrolled | Russian Federation: 82 |
| Country: Number of subjects enrolled | Japan: 71              |
| Worldwide total number of subjects   | 289                    |
| EEA total number of subjects         | 12                     |

Notes:

### Subjects enrolled per age group

|   |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 282 |
| From 65 to 84 years                       | 7   |

|                   |   |
|-------------------|---|
| 85 years and over | 0 |
|-------------------|---|

## Subject disposition

### Recruitment

Recruitment details:

subjects must have completed the 6-week double-blind phase of study D1001066 and must have completed all required assessments on the final study visit

### Pre-assignment

Screening details:

Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Anxiety/depression) at each post-baseline visit

### Period 1

|                              |   |
|------------------------------|---|
| Period 1 title               | Overall Study-Open Label (overall period) |
| Is this the baseline period? | Yes                                       |
| Allocation method            | Not applicable                            |
| Blinding used                | Not blinded                               |

### Arms

|           |            |
|-----------|------------|
| Arm title | lurasidone |
|-----------|------------|

Arm description:

Flexible doses (40 or 80 mg/day)

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | lurasidone   |
| Investigational medicinal product code |              |
| Other name                             | Latuda       |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

flexible dose (40 or 80 mg/day)

| Number of subjects in period 1 | lurasidone |
|--------------------------------|------------|
| Started                        | 289        |
| Completed                      | 235        |
| Not completed                  | 54         |
| Consent withdrawn by subject   | 28         |
| Adverse event, non-fatal       | 17         |
| reason not given               | 4          |
| Lack of efficacy               | 4          |
| Protocol deviation             | 1          |

## Baseline characteristics

### Reporting groups

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | Overall Study-Open Label |
|-----------------------|--------------------------|

Reporting group description: -

| Reporting group values                             | Overall Study-Open Label | Total |  |
|--|--------------------------|-------|--|
| Number of subjects                                 | 289                      | 289   |  |
| Age categorical                                    |                          |       |  |
| Units: Subjects                                    |                          |       |  |
| In utero   | 0                        | 0     |  |
| Preterm newborn infants (gestational age < 37 wks) | 0                        | 0     |  |
| Newborns (0-27 days)                               | 0                        | 0     |  |
| Infants and toddlers (28 days-23 months)           | 0                        | 0     |  |
| Children (2-11 years)                              | 0                        | 0     |  |
| Adolescents (12-17 years)                          | 0                        | 0     |  |
| Adults (18-64 years)                               | 282                      | 282   |  |
| From 65-84 years                                   | 7                        | 7     |  |
| 85 years and over                                  | 0                        | 0     |  |
| Age continuous                                     |                          |       |  |
| Units: years                                       |                          |       |  |
| arithmetic mean                                    | 40.1                     |       |  |
| standard deviation                                 | ± 11.23                  | -     |  |
| Gender categorical                                 |                          |       |  |
| Units: Subjects                                    |                          |       |  |
| Female   | 144                      | 144   |  |
| Male   | 145                      | 145   |  |

## End points

### End points reporting groups

|                                  |            |
|----------------------------------|------------|
| Reporting group title            | lurasidone |
| Reporting group description:     |            |
| Flexible doses (40 or 80 mg/day) |            |

### Primary: Frequency of Adverse Events (AEs) or treatment related AEs, extrapyramidal AEs, SAEs, and AEs leading to study discontinuation

|                 |   |
|-----------------|---|
| End point title | Frequency of Adverse Events (AEs) or treatment related AEs, extrapyramidal AEs, SAEs, and AEs leading to study discontinuation <sup>[1]</sup> |
|-----------------|---|

End point description:

|                      |         |
|----------------------|---------|
| End point type       | Primary |
| End point timeframe: |         |
| Overall study        |         |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: this was an open label study - there was no statistical analysis required

| End point values                                  | lurasidone         |  |  |  |
|---|--------------------|--|--|--|
| Subject group type                                | Reporting group    |  |  |  |
| Number of subjects analysed                       | 289 <sup>[2]</sup> |  |  |  |
| Units: events                                     |                    |  |  |  |
| Frequency of Adverse Events                       | 146                |  |  |  |
| Frequency of treatment-related Adverse Events     | 100                |  |  |  |
| Frequency of extrapyramidal Adverse Events        | 28                 |  |  |  |
| Frequency of Serious Adverse Events               | 14                 |  |  |  |
| Frequency of AEs leading to study discontinuation | 18                 |  |  |  |

Notes:

[2] - safety population

### Statistical analyses

No statistical analyses for this end point

### Primary: Proportion of subjects using concomitant antiparkinsonian drugs

|                 |  |
|-----------------|--|
| End point title | Proportion of subjects using concomitant antiparkinsonian drugs <sup>[3]</sup> |
|-----------------|--|

End point description:

|                      |         |
|----------------------|---------|
| End point type       | Primary |
| End point timeframe: |         |
| overall study        |         |

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: this was an open label study - there was no statistical analysis required

|   |                    |  |  |  |
|---|--------------------|--|--|--|
| <b>End point values</b>                           | lurasidone         |  |  |  |
| Subject group type                                | Reporting group    |  |  |  |
| Number of subjects analysed                       | 289 <sup>[4]</sup> |  |  |  |
| Units: participants                               |                    |  |  |  |
| Subjects using concomitant antiparkinsonian drugs | 21                 |  |  |  |

Notes:

[4] - safety population

## Statistical analyses

No statistical analyses for this end point

## Primary: Change from Open-label and Double-blind Baseline in Drug-Induced Extrapyrimal Symptoms Scale

|                          |  |
|--------------------------|--|
| End point title          | Change from Open-label and Double-blind Baseline in Drug-Induced Extrapyrimal Symptoms Scale <sup>[5]</sup>  |
| End point description:   | Change from Open-label and Double-blind Baseline in Drug-Induced Extrapyrimal Symptoms Scale (DIEPSS) total score (excluding the overall severity) at each post-baseline visit |
| End point type           | Primary  |
| End point timeframe:     |  |
| Up to day 92 (follow-up) |  |

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: this was an open label study - there was no statistical analysis required

|                                      |                    |  |  |  |
|--------------------------------------|--------------------|--|--|--|
| <b>End point values</b>              | lurasidone         |  |  |  |
| Subject group type                   | Reporting group    |  |  |  |
| Number of subjects analysed          | 289 <sup>[6]</sup> |  |  |  |
| Units: score                         |                    |  |  |  |
| arithmetic mean (standard deviation) |                    |  |  |  |
| Day 1                                | 0.4 (± 1.15)       |  |  |  |
| Day 8                                | 0.4 (± 1.18)       |  |  |  |
| Day 15                               | 0.5 (± 1.28)       |  |  |  |
| Day 29                               | 0.4 (± 1.08)       |  |  |  |
| Day 57                               | 0.4 (± 1.17)       |  |  |  |
| Day 85                               | 0.4 (± 1.13)       |  |  |  |
| Day 92 (follow-up)                   | 0.3 (± 0.81)       |  |  |  |

Notes:

[6] - safety population

## Statistical analyses

No statistical analyses for this end point

## Primary: Frequency of subjects with suicidal behavior and suicidal ideation

|  |   |
|--|---|
| End point title  | Frequency of subjects with suicidal behavior and suicidal ideation <sup>[7]</sup> |
| End point description:<br>Change from Open-label and Double-blind Baseline in Drug-Induced Extrapyramidal Symptoms Scale measured by Columbia-Suicide Severity Rating Scale (C-SSRS) |   |
| End point type   | Primary   |
| End point timeframe:   |   |
| Overall study  |   |

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: this was an open label study - there was no statistical analysis required

|                             |                    |  |  |  |
|-----------------------------|--------------------|--|--|--|
| <b>End point values</b>     | lurasidone         |  |  |  |
| Subject group type          | Reporting group    |  |  |  |
| Number of subjects analysed | 289 <sup>[8]</sup> |  |  |  |
| Units: events               |                    |  |  |  |
| Suicidal behavior           | 1                  |  |  |  |
| Suicidal ideation           | 7                  |  |  |  |

Notes:

[8] - safety population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Open-label and Double-blind baseline in (PANSS) score at each baseline visit

|   |  |
|---|--|
| End point title   | Change from Open-label and Double-blind baseline in (PANSS) score at each baseline visit |
| End point description:<br>Change from Open-label and Double-blind baseline in Positive and Negative Syndrome Scale (PANSS) score at each baseline visit |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Open-label (OL) Baseline, Double-blind (DB) Baseline, Week 1, Week 2, Week4, Week 8, Week 12, Week 1 (LOCF)   |  |

|                                     |                    |  |  |  |
|-------------------------------------|--------------------|--|--|--|
| <b>End point values</b>             | lurasidone         |  |  |  |
| Subject group type                  | Reporting group    |  |  |  |
| Number of subjects analysed         | 287 <sup>[9]</sup> |  |  |  |
| Units: units on a scale             |                    |  |  |  |
| least squares mean (standard error) |                    |  |  |  |
| Double-Blind Baseline               | 101.1 (± 11.00)    |  |  |  |
| Open-Label Baseline                 | 80.5 (± 15.80)     |  |  |  |
| Week 1                              | 79.0 (± 16.45)     |  |  |  |
| Week 2                              | 75.9 (± 16.09)     |  |  |  |
| Week 4                              | 73.9 (± 15.29)     |  |  |  |



|                |                |  |  |  |
|----------------|----------------|--|--|--|
| Week 8         | 71.5 (± 15.70) |  |  |  |
| Week 12        | 68.9 (± 15.72) |  |  |  |
| Week 12 (LOCF) | 71.7 (± 18.22) |  |  |  |

Notes:

[9] - ITT population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Open-label and Double-blind Baseline in (CGI-S)score at each post-baseline visit

|  |  |
|--|--|
| End point title  | Change from Open-label and Double-blind Baseline in (CGI-S)score at each post-baseline visit |
| End point description:<br>Change from Open-label and Double-blind Baseline in Clinical Global Impression-Severity Scale (CGI-S)score at each post-baseline visit |  |
| End point type   | Secondary  |
| End point timeframe:<br>Open-label (OL) Baseline, Double-blind (DB) Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF)                            |  |

| End point values                    | lurasidone          |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[10]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double blind baseline               | 4.9 (± 0.60)        |  |  |  |
| Open-label baseline                 | 3.9 (± 0.89)        |  |  |  |
| Week 1                              | 3.8 (± 0.87)        |  |  |  |
| Week 2                              | 3.7 (± 0.84)        |  |  |  |
| Week 4                              | 3.5 (± 0.85)        |  |  |  |
| Week 8                              | 3.4 (± 0.82)        |  |  |  |
| Week 12                             | 3.3 (± 0.82)        |  |  |  |
| Week 12 (LOCF)                      | 3.4 (± 0.92)        |  |  |  |

Notes:

[10] - ITT population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Open-label and Double-blind Baseline in PANSS subscale scores (Positive scale) at each post-baseline visit

|  |  |
|--|--|
| End point title                          | Change from Open-label and Double-blind Baseline in PANSS subscale scores (Positive scale) at each post-baseline visit |
| End point description:<br>Positive scale |  |
| End point type                           | Secondary  |

End point timeframe:

Double-blind Baseline, Open-label Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF)

| End point values                    | lurasidone          |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[11]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 25.3 (± 3.80)       |  |  |  |
| Open-label baseline                 | 19.0 (± 5.31)       |  |  |  |
| Week 1                              | 18.5 (± 5.42)       |  |  |  |
| Week 2                              | 17.5 (± 5.06)       |  |  |  |
| Week 4                              | 17.0 (± 4.73)       |  |  |  |
| Week 8                              | 16.1 (± 4.56)       |  |  |  |
| Week 12                             | 15.6 (± 4.68)       |  |  |  |
| Week 12 (LOCF)                      | 16.4 (± 5.50)       |  |  |  |

Notes:

[11] - ITT population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Open-label and Double-blind Baseline in PANSS subscale scores (Negative scale) at each post-baseline visit

|                 |  |
|-----------------|--|
| End point title | Change from Open-label and Double-blind Baseline in PANSS subscale scores (Negative scale) at each post-baseline visit |
|-----------------|--|

End point description:

Negative scale

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Double-blind baseline, Open-label baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF)

| End point values                    | lurasidone          |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[12]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 24.2 (± 4.08)       |  |  |  |
| Open-label baseline                 | 20.7 (± 4.49)       |  |  |  |
| Week 1                              | 20.4 (± 4.53)       |  |  |  |
| Week 2                              | 19.7 (± 4.67)       |  |  |  |
| Week 4                              | 19.3 (± 4.57)       |  |  |  |
| Week 8                              | 18.8 (± 4.65)       |  |  |  |

|                |               |  |  |  |
|----------------|---------------|--|--|--|
| Week 12        | 18.3 (± 4.59) |  |  |  |
| Week 12 (LOCF) | 18.9 (± 4.95) |  |  |  |

Notes:

[12] - ITT population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Open-label and Double-blind Baseline in PANSS subscale scores (General psychopathology scale) at each post-baseline visit

|                 |   |
|-----------------|---|
| End point title | Change from Open-label and Double-blind Baseline in PANSS subscale scores (General psychopathology scale) at each post-baseline visit |
|-----------------|---|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Double-blind baseline, Open-label baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF)

|                                     |                     |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| <b>End point values</b>             | lurasidone          |  |  |  |
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[13]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 51.5 (± 6.41)       |  |  |  |
| Open-label baseline                 | 40.9 (± 8.29)       |  |  |  |
| Week 1                              | 40.2 (± 8.56)       |  |  |  |
| Week 2                              | 38.7 (± 8.46)       |  |  |  |
| Week 4                              | 37.7 (± 8.01)       |  |  |  |
| Week 8                              | 35.1 (± 8.33)       |  |  |  |
| Week 12                             | 36.5 (± 9.58)       |  |  |  |

Notes:

[13] - ITT population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Open-label and Double-blind Baseline in PANSS subscale scores (Negative symptom scale) at each post-baseline visit

|                 |  |
|-----------------|--|
| End point title | Change from Open-label and Double-blind Baseline in PANSS subscale scores (Negative symptom scale) at each post-baseline visit |
|-----------------|--|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Double-blind baseline, Open-label baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF)

| End point values                    | lurasidone          |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[14]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 21.1 (± 3.75)       |  |  |  |
| Open-label baseline                 | 17.4 (± 4.09)       |  |  |  |
| Week 1                              | 17.1 (± 4.16)       |  |  |  |
| Week 2                              | 16.7 (± 4.16)       |  |  |  |
| Week 4                              | 16.3 (± 4.12)       |  |  |  |
| Week 8                              | 15.9 (± 4.24)       |  |  |  |
| Week 12                             | 15.3 (± 4.10)       |  |  |  |
| Week 12 (LOCF)                      | 15.8 (± 4.42)       |  |  |  |

Notes:

[14] - ITT population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Excitement) at each post-baseline visit

|                 |   |
|-----------------|---|
| End point title | Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Excitement) at each post-baseline visit |
|-----------------|---|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Double-blind baseline, Open-label baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF)

| End point values                    | lurasidone          |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[15]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 11.5 (± 2.90)       |  |  |  |
| Open-label baseline                 | 8.9 (± 3.16)        |  |  |  |
| Week 1                              | 8.7 (± 3.26)        |  |  |  |
| Week 2                              | 8.4 (± 3.12)        |  |  |  |
| Week 4                              | 8.1 (± 2.85)        |  |  |  |

|                |              |  |  |  |
|----------------|--------------|--|--|--|
| Week 8         | 7.7 (± 2.82) |  |  |  |
| Week 12        | 7.5 (± 2.92) |  |  |  |
| Week 12 (LOCF) | 7.9 (± 3.29) |  |  |  |

Notes:

[15] - ITT population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Cognitive disorders) at each post-baseline visit

|                 |  |
|-----------------|--|
| End point title | Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Cognitive disorders) at each post-baseline visit |
|-----------------|--|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Double-blind baseline, Open-label baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF)

|                                     |                     |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| <b>End point values</b>             | lurasidone          |  |  |  |
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[16]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 16.3 (± 2.67)       |  |  |  |
| Open-label baseline                 | 13.8 (± 3.15)       |  |  |  |
| Week 1                              | 13.7 (± 3.14)       |  |  |  |
| Week 2                              | 13.2 (± 3.29)       |  |  |  |
| Week 4                              | 13.0 (± 3.00)       |  |  |  |
| Week 8                              | 12.6 (± 2.90)       |  |  |  |
| Week 12                             | 12.2 (± 3.29)       |  |  |  |
| Week 12 (LOCF)                      | 12.6 (± 3.29)       |  |  |  |

Notes:

[16] - ITT population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Positive symptoms) at each post-baseline visit

|                 |  |
|-----------------|--|
| End point title | Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Positive symptoms) at each post-baseline visit |
|-----------------|--|

End point description:

|   |           |
|---|-----------|
| End point type  | Secondary |
| End point timeframe:  |           |
| Double-blind baseline, Open-label baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF) |           |

|                                     |                     |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| <b>End point values</b>             | lurasidone          |  |  |  |
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[17]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 15.7 (± 2.38)       |  |  |  |
| Open-label baseline                 | 15.7 (± 11.9)       |  |  |  |
| Week 1                              | 11.5 (± 3.41)       |  |  |  |
| Week 2                              | 10.9 (± 3.16)       |  |  |  |
| Week 4                              | 10.5 (± 3.13)       |  |  |  |
| Week 8                              | 10.0 (± 3.07)       |  |  |  |
| Week 12                             | 9.6 (± 3.11)        |  |  |  |
| Week 12 (LOCF)                      | 10.1 (± 3.52)       |  |  |  |

Notes:

[17] - ITT population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Anxiety/depression) at each post-baseline visit

|                 |   |
|-----------------|---|
| End point title | Change from Open-label and Double-blind Baseline in PANSS five-factor model scores (Anxiety/depression) at each post-baseline visit |
|-----------------|---|

End point description:

|   |           |
|---|-----------|
| End point type  | Secondary |
| End point timeframe:  |           |
| Double-blind baseline, Open-label baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 12 (LOCF) |           |

|                                     |                     |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| <b>End point values</b>             | lurasidone          |  |  |  |
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[18]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 16.1 (± 3.33)       |  |  |  |
| Open-label baseline                 | 12.0 (± 3.51)       |  |  |  |
| Week 1                              | 11.8 (± 3.48)       |  |  |  |
| Week 2                              | 11.3 (± 3.43)       |  |  |  |

|                |                    |  |  |  |
|----------------|--------------------|--|--|--|
| Week 4         | 11.1 ( $\pm$ 3.24) |  |  |  |
| Week 8         | 10.8 ( $\pm$ 3.30) |  |  |  |
| Week 12        | 10.3 ( $\pm$ 3.46) |  |  |  |
| Week 12 (LOCF) | 10.8 ( $\pm$ 3.80) |  |  |  |

Notes:

[18] - ITT population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Open-label and Double-blind Baseline in Calgary Depression Scale for Schizophrenia (CDSS) total scores at each post-baseline visit

|                 |  |
|-----------------|--|
| End point title | Change from Open-label and Double-blind Baseline in Calgary Depression Scale for Schizophrenia (CDSS) total scores at each post-baseline visit |
|-----------------|--|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Double-blind baseline, Open-label baseline, Week 4, Week 12, Week 12 (LOCF)

| End point values                    | lurasidone          |  |  |  |
|-------------------------------------|---------------------|--|--|--|
| Subject group type                  | Reporting group     |  |  |  |
| Number of subjects analysed         | 287 <sup>[19]</sup> |  |  |  |
| Units: units on a scale             |                     |  |  |  |
| least squares mean (standard error) |                     |  |  |  |
| Double-blind baseline               | 4.1 ( $\pm$ 3.73)   |  |  |  |
| Open-label baseline                 | 2.4 ( $\pm$ 2.85)   |  |  |  |
| Week 4                              | 2.2 ( $\pm$ 3.02)   |  |  |  |
| Week 12                             | 1.8 ( $\pm$ 2.70)   |  |  |  |
| Week 12 (LOCF)                      | 2.0 ( $\pm$ 2.84)   |  |  |  |

Notes:

[19] - ITT population

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

During the 12 week treatment period

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 19.1 |
|--------------------|------|

### Reporting groups

|                       |            |
|-----------------------|------------|
| Reporting group title | lurasidone |
|-----------------------|------------|

Reporting group description:

Flexible doses (40 or 80 mg/day)

| Serious adverse events                            | lurasidone       |  |  |
|---|------------------|--|--|
| Total subjects affected by serious adverse events |                  |  |  |
| subjects affected / exposed                       | 14 / 289 (4.84%) |  |  |
| number of deaths (all causes)                     | 0                |  |  |
| number of deaths resulting from adverse events    | 0                |  |  |
| Psychiatric disorders                             |                  |  |  |
| Schizophrenia                                     |                  |  |  |
| subjects affected / exposed                       | 12 / 289 (4.15%) |  |  |
| occurrences causally related to treatment / all   | 7 / 15           |  |  |
| deaths causally related to treatment / all        | 0 / 0            |  |  |
| Impulsive behaviour                               |                  |  |  |
| subjects affected / exposed                       | 1 / 289 (0.35%)  |  |  |
| occurrences causally related to treatment / all   | 1 / 1            |  |  |
| deaths causally related to treatment / all        | 0 / 0            |  |  |
| Suicide attempt                                   |                  |  |  |
| subjects affected / exposed                       | 1 / 289 (0.35%)  |  |  |
| occurrences causally related to treatment / all   | 1 / 1            |  |  |
| deaths causally related to treatment / all        | 0 / 0            |  |  |
| Anxiety   |                  |  |  |
| subjects affected / exposed                       | 1 / 289 (0.35%)  |  |  |
| occurrences causally related to treatment / all   | 0 / 1            |  |  |
| deaths causally related to treatment / all        | 0 / 0            |  |  |



Frequency threshold for reporting non-serious adverse events: 5 %

|   |                   |  |  |
|---|-------------------|--|--|
| <b>Non-serious adverse events</b>                     | lurasidone        |  |  |
| Total subjects affected by non-serious adverse events |                   |  |  |
| subjects affected / exposed                           | 36 / 289 (12.46%) |  |  |
| Nervous system disorders                              |                   |  |  |
| Akathisia   |                   |  |  |
| subjects affected / exposed                           | 19 / 289 (6.57%)  |  |  |
| occurrences (all)                                     | 20                |  |  |
| Infections and infestations                           |                   |  |  |
| Nasopharyngitis                                       |                   |  |  |
| subjects affected / exposed                           | 17 / 289 (5.88%)  |  |  |
| occurrences (all)                                     | 19                |  |  |

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported